Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant PD-1 antibody plus chemotherapy in resectable head and neck squamous cell carcinoma
ChiCTR2100046105Phase 2Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by First Hospital of China Medical University. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
fluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100046105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046105.